Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Nat Immunol. 2009 May 31;10(7):769–777. doi: 10.1038/ni.1743

Figure 6. S1P1 induces activation of Akt-mTOR to inhibit Treg development and function.

Figure 6

(a) IL-2 activated signaling pathways in thymic Treg precursors from WT and S1P1-Tg mice. CD4+CD25+Foxp3 cells were purified and stimulated with medium alone or IL-2, and activation of Akt, STAT5, Erk and S6 ribosomal protein (S6) were examined by flow cytometry using phospho-specific antibodies. Data are representative of 4 independent experiments. (b) Effects of drug treatments on IL-2 induced Foxp3 expression in Treg precursors. CD4+CD25+Foxp3 cells were treated with U0126, LY294002 and Rapamycin for 30 minutes, followed by IL-2 stimulation. Data are representative of 3 independent experiments. (c) IL-2 activated signaling pathways in peripheral Treg cells from WT and S1P1-Tg mice. Treg cells were stimulated with medium alone or IL-2, and activation of Akt, STAT5, Erk and S6 ribosomal protein (S6) were examined by flow cytometry using phospho-specific antibodies. Data are representative of 5 independent experiments. (d) Suppressive activity of Treg cells transduced with dn-Akt retrovirus. WT and S1P1-Tg Treg cells were transduced with control (MiT) and dn-Akt expressing (dn-Akt) retroviruses (non-transduced cells are shown on the right as a comparison), and transduced cells were sorted and used in the T-cell suppression assays with different Tconv and Treg ratios. Data are representative of 3 independent experiments. *, P < 0.001 (Student’s t-test).

HHS Vulnerability Disclosure